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Abstract
A large body of work has been published on transplantation of a wide range of neural stem and 
progenitor cell types derived from the developing and adult CNS, as well as from pluripotent 
embryonic stem cells, in models of traumatic spinal cord injury (SCI). However, many of these 
cell-based approaches present practical issues for clinical translation such as ethical cell 
derivation, generation of potentially large numbers of homogenously prepared cells, and immune 
rejection. With the advent of induced Pluripotent Stem (iPS) cell technology, many of these issues 
may potentially be overcome. To date, a number of studies have demonstrated integration, 
differentiation into mature CNS lineages, migration and long-term safety of iPS cell transplants in 
a variety of SCI models, as well as therapeutic benefits in some cases. Given the clinical potential 
of this advance in stem cell biology, we present a concise review of studies published to date 
involving iPS cell transplantation in animal models of SCI.
Introduction
Traumatic spinal cord injury (SCI) and its motor, sensory and autonomic consequences have 
a devastating impact on patient quality of life [1]. In the United States alone, there are 
around 276,000 individuals currently living with SCI (with even higher published estimates) 
and approximately 12,500 new cases per year [2]. Major causes of SCI include vehicular 
accidents, falls, sports injuries and violence [1]. SCI represents a heterogeneous set of 
conditions resulting from differences in the location, type and severity of trauma, as well as 
on the consequent types and degree of functional impairment. As the central nervous system 
(CNS) has limited potential to spontaneously regenerate, a first line treatment for SCI 
patients often involves interventions such as surgical stabilization and decompression and 
high dose methylprednisolone, followed by long-term approaches such as physical 
rehabilitation and pharmacological treatments for problems like chronic neuropathic pain 
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[3]. Although used, controversies on the efficacy of therapies such as methylprednisolone 
and decompression remain [4].
To overcome the non-regenerative state of the CNS, cell transplantation provides a 
potentially powerful approach to repair and/or replace damaged elements of the injured 
spinal cord. A number of these transplant-based interventions using cell types derived from 
the developing and adult CNS, as well as from pluripotent embryonic (ES) stem cells, have 
demonstrated therapeutic efficacy in various animal models of SCI [5]. Despite success with 
many of these cell types, practical issues including ethical derivation, necessity for long-
term immunosuppression of the patient recipient, and isolation and expansion of large 
numbers of cells in a uniform manner are impediments to clinical translation. With the 
advent of induced Pluripotent Stem (iPS) cell technology [6], many of these issues may 
potentially be overcome. Given the clinical relevance of this advance in stem cell biology, 
we will review studies published to date involving iPS cell transplantation in animal models 
of traumatic SCI.
Spinal cord injury pathophysiology
SCI progression generally consists of three major temporal phases [7]. The primary injury is 
characterized by direct tissue trauma, resulting in early loss of various CNS cell types, 
axotomy of passing axonal fibers, and blood vessel and blood brain barrier disruption [8, 9]. 
The initial trauma sets into course a sequence of secondary pathological events that occur 
over the hours, days and even weeks following injury, causing significant additional 
degeneration and consequent functional loss [7]. A large number of underlying cellular 
mechanisms are responsible for secondary injury processes, including excitotoxicity, 
immune cell activation, and oxidative damage [10]. In the chronic stages following SCI, 
little-to-no long-term recovery occurs due to issues such as minimal axonal growth/
regeneration, modest functional remyelination, and lack of a robust response by endogenous 
neural stem and progenitor cells [11–16].
Cell transplantation as a therapy for SCI
Cell transplantation provides a therapeutic tool to target a number of these SCI pathological 
processes. Transplants can (1) replace damaged and loss CNS cell types (2), provide 
neurotrophic support and modulate the host immune response to minimize secondary injury, 
(3) enhance axonal plasticity by reducing the growth inhibitory environment of the injured 
spinal cord and by providing a cellular substrate for axonal extension in the lesion site, 
amongst a number of other potential benefits [17, 18]. To date, a variety of cell types have 
been tested in models of SCI to varying degrees of success. These include neural cells types 
such as peripheral nerve grafts, Schwann cells [19–21], olfactory ensheathing glia [22–25], 
dissociated fetal tissue, multipotent neural stem cells (NSCs), lineage-restricted neural 
progenitor cells (NPCs), and mature CNS cells. In addition, non-neural cell classes have also 
been tested, including genetically-modified fibroblasts, bone marrow stromal cells and 
activated macrophages. NSCs and NPCs are particularly promising sources for SCI given 
that they can actually replace mature CNS cell types, as well as contribute to other beneficial 
processes such as immune modulation.
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Background on iPS cell technology
Nearly 10 years ago, the laboratory of Shinya Yamanaka developed a method for the in vitro 
conversion of adult rodent somatic cells into pluripotent ES cell-like cells (termed “induced 
Pluripotent Stem cells” or “iPS cells”) via retroviral introduction of several pluripotency 
related genes - Oct3/4, Sox2, c-Myc and Klf48 [6]. This work was then extended to the 
generation of human iPS cells using a similar combination of pluripotency factors [26]. 
NSCs and NPCs have traditionally been obtained from fetal or adult nervous system tissue 
or from pluripotent ES cells, all of which are associated with ethical concerns and practical 
issues of standardization and generation of adequate numbers of cells for transplantation in 
potentially large numbers of patients. iPS cell technology allows for homogeneous 
derivation of cell types in large quantities for applications such as therapeutic 
transplantation, potentially in an autologous fashion from the eventual patient recipient [27–
31].
However, iPS cell use of is not devoid of risks. One of the main concerns regarding this 
technology is the potential for uncontrolled proliferation and even tumor formation given 
their pluripotent state (ES cells present a similar concern) [32, 33]. Also, the use of viral 
vectors that can integrate randomly into host genome could disrupt important regulators of 
cell division such as tumor suppressors or could result in the activation of oncogenes [6, 34, 
35]. In addition, iPS cell generation involves the introduction of factors that regulate the 
cell’s proliferative state, and so it is imperative when using this method that there is a tight 
screening of oncogenic capacity prior to transplantation [36]. Alternative strategies are being 
developed to minimize this risk. PiggyBac transposition [37, 38], episomal vectors [39–44], 
microRNA [45, 46], and delivery of recombinant reprogramming proteins [47–49] are 
examples of these new methods. More recently, small-molecule compounds like 
CHIR99021 (glycogen synthase kinase 3 inhibitor), RepSox (TGF-β inhibitor), DZNep (s-
adenosylhomocysteine hydrolase inhibitor), valproic acid (histone deacetylase inhibitor), 
tranylcypromine (lysine-specific demethylase 1 inhibitor), forskolin (adenylate cyclase 
activator) and TTNPB (retinoic acid receptor ligand) have been used to generate iPS cells 
[50]. More extensive discussion of these issues are available [44]. These new methods can 
reduce the risk of malignant transformation of transplanted cells and can serve as 
alternatives to “classic” viral transduction. Also, emerging iPS cell technologies that require 
less time to induce pluripotency (and subsequently to differentiate the iPS cells into mature 
cell types of interest) would provide much needed methodological improvements for 
achieving autologous transplantation at earlier stages of disease in conditions such as SCI.
Overview of iPS cell transplantation in SCI models
Despite the promise of this approach, the iPS cell transplantation field is in its infancy with 
respect to evaluating long-term in vivo integration and therapeutic usefulness in relevant SCI 
models. A number of studies have reported significant therapeutic benefit when NSCs/NPCs 
derived from either mouse [33] or human [36, 51, 52] iPS cells were transplanted into 
contusion or cavity-type models of rodent SCI, as well as in non-human primate models 
[53]. Given the xenografting paradigm, most studies of iPS cell transplantation in SCI 
animal models have employed either immunosuppressed rodents or animals with a 
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genetically-compromised immune response. In many cases, cells were delivered in a 
multipotent NSC-like state and resulted in mixed differentiation into glial phenotypes, 
including astrocytes, and various neuronal subtypes. Across all of these published studies, 
the phenotypic state of cells (derived in vitro from iPS cells prior to injection) at the time of 
transplantation into injured spinal cord ranged from undifferentiated neurospheres [53], 
NSCs [52], mixed cell lineages to even astrocytes only [54]. While these studies were able 
to achieve some functional benefit, future work may require more phenotypically targeted 
strategies, each of which depends on the nature of the SCI pathology (e.g. type of injury, 
anatomical locations affected, etc.) and the specific cell lineages being targeted for 
replacement. Nevertheless, these studies have collectively demonstrated therapeuitc 
properties of iPS cell-derived transplants in the injured spinal cord environment, including 
synaptic integration into endogenous neuronal circuitry [36, 51].
Therapeutic effects of iPS cell transplantation in SCI
Following transplantation of human iPS cell-derived neurospheres into an immunodeficient 
mouse model of SCI, Nori and colleagues demonstrated functional efficacy that was 
accompanied by a variety of histopathological improvements, including decreased neuronal 
death and demyelination and increased angiogenesis and axonal growth [36]. Transplanted 
cells survived for prolonged lengths of time and differentiated into various mature CNS 
lineages. Transplants also secreted a variety of neurotrophic factors, including NT3, NT4, 
CNTF, VEGF and PECAM, which may explain, for example, the increased angiogenesis 
and axonal growth observed in both this study and by Kobayashi et al. in the marmoset 
contusion SCI model [53]. Using a model of thoracic contusion SCI in rats, Romanyuk and 
colleagues showed that transplantation of iPS cell-derived NPCs one week post-SCI 
promoted tissue sparing and improvement in a number of functional motor tests, even 
though only approximately 10% of transplanted cells survived in injured spinal cord [52]. 
Similar to the neurotrophin production noted in the Nori study, the authors observed 
increased levels of human-specific neurotrophic factors, possibly underlying the observed 
therapeutic benefit. Together, these findings point to the multi-faceted potential of 
transplanted iPS cells in SCI; not only are they capable of replacing lost cell types, but they 
are also able to modulate the environment of the injured host spinal cord.
In the majority of studies involving iPS cell transplantation in SCI models, significant graft 
survival, integration and, often times, migration from injection sites were observed. Using a 
thoracic spinal contusion model in Nonobese diabetic-severe combined immunodeficiency 
(NOD-SCID) mice, Fujimoto and colleagues showed that transplantation of human iPS-
derived neuroepithelial-like NSCs promotes functional motor recovery via integration of 
transplant-derived neurons and connection with host neuronal circuitry [51]. Along these 
lines, Lu and colleagues showed results indicating that even iPS cells derived from older 
subjects can be used successfully for SCI treatment. After a C5 hemisection, human iPS 
cell-derived NSCs from an 86 year-old were transplanted into adult immunodeficient rats. 
At 3 months follow-up, transplanted cells survived and the cells that differentiated into 
neurons showed long-distance axonal outgrowth and made extensive synaptic connections 
with host neurons, even outside of the lesion area [55]. Tang and colleagues transplanted 
human iPS cell-derived NSCs labelled in vitro with superparamagnetic iron oxide particles 
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into both a rat model of traumatic brain injury and a monkey model of SCI at 1 week post-
injury. Using recurrent in vivo magnetic resonance imaging (MRI) tracking until 30 days 
post-injury, the authors showed that transplant-derived cells could progressively migrate 
from injection sites, which was accompanied by significant motor function recovery [56]. 
Despite the graft integration shown in these studies, it has yet to be mechanistically 
determined how these cells are promoting therapeutic effects. It may, for example, be that 
long-term graft integration and cell replacement of mature CNS lineages are not even 
necessary if transplanted cells can exert benefit via transient processes such as 
neuroprotection. This issue, however, is not unique to transplantation of iPS cells, but it 
relevant to NSC/NPC transplantation in general in SCI and other CNS diseases.
Studies to date using iPS cell transplantation in SCI models have not focused on astrocyte 
replacement. To begin to utilize astrocyte replacement in a mechanistically-targeted fashion 
based on their crucial functions in the intact nervous system, we transplanted human iPS 
cell-derived astrocytes (hiPSAs) as a strategy for restoring extracellular glutamate 
homeostasis in the injured spinal cord. Astrocytes are responsible for the vast majority of 
glutamate uptake throughout the CNS via expression of the plasma membrane transporter, 
glutamate transporter 1 (GLT1), thereby playing a central role in maintaining normal 
synaptic communication and preventing glutamate-mediated excitotoxicity. Following SCI, 
astrocyte GLT1 expression and function are severely compromised, which contributes to 
excitotoxicity-induced cell death during the delayed secondary injury phase. We derived 
pluripotent iPS cells from non-diseased human donors, subsequently generated glial 
progenitors and then differentiated these cells into hiPSAs prior to transplantation. In a 
unilateral cervical contusion model of rat SCI, we injected hiPSAs engineered to 
overexpress GLT1 into the cervical ventral horn as a therapeutic strategy for reconstituting 
GLT1 function, preventing excitotoxicity, and consequently protecting respiratory phrenic 
motor neurons and preserving diaphragm function. Transplants survived for long periods of 
time in the injured cervical spinal cord, did not form tumors or show uncontrolled 
proliferation, differentiated into only GFAP-positive astrocytes, and did not localize to 
ectopic locations or differentiate into unexpected lineages. GLT1 overexpressing hiPSAs 
(engineered using an AAV8- GLT1 vector in vitro prior to injection) expressed persistently 
high levels of GLT1 protein following transplantation, and overexpression also enhanced 
GLT1-mediated glutamate uptake compared to control cells. Furthermore, these 
overexpressing hiPSA transplants promoted significant survival of phrenic motor neurons, 
preservation of diaphragm neuromuscular junction innervation, and protection of 
diaphragmatic respiratory function. Our findings demonstrate the therapeutic value of 
targeting mature astrocyte properties using iPS cell transplantation in the injured spinal cord. 
Given the long list of important astrocyte functions, this strategy represents just one example 
of using this astrocyte-targeted approach in SCI.
Collectively, these studies indicate the therapeutic utility of iPS cell-derived transplantation 
for SCI potentially via properties such as differentiation into mature CNS cell types, 
neuronal integration into host circuitry, production of neurotrophic factors, and distribution 
from injection sites to areas of pathology.
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Lack of therapeutic effects / negative effects of iPS cell transplantation in 
SCI
Not all studies with iPS cell transplantation reported beneficial outcomes in SCI models. 
Pomeshchik and colleagues did not observe improved function when human iPS cell-derived 
NPCs were transplanted 7 days after contusion SCI [57]. However, the authors also did not 
find long-term survival of grafted cells in these mice receiving a Tacrolimus immune 
suppression regimen. Contrary to this report, a number of studies employing human iPS cell-
derived transplants have noted significant survival and differentiation into mature CNS cell 
types following injection into the adult spinal cord of immunosuppressed rodents [58, 59]. In 
our study with hiPSAs described above, we also observed robust and persistent transplant 
integration in the contused spinal cord using a modified immune suppression protocol 
consisting of both Tacrolimus and Rapamycin in mice or cyclosporine only in rats. 
Transplant rejection due to immunesuppression regimen problems may not be relevant to 
autologous delivery; nevertheless, it is unlikely that autologous transplantation will be used 
in all cases because of issues such as minimal time available between trauma and 
transplantation (as discussed below). It will therefore be crucial to address this important 
issue in animal models prior to clinical translation.
A study from the Horner group [60] reported lack of therapeutic improvement with 
transplantation of human iPS cell-derived NPCs in a SCI model, despite significant graft 
integration. However, cells were delivered at a chronic time point following injury, which 
may represent an environment less amenable to transplant-induced plasticity than delivery at 
very early stages post-trauma. As for any cell-based intervention, the timing of iPS cell 
transplantation will have important therapeutic consequences. The temporal delivery 
paradigm will depend on both the disease mechanism(s) being targeting (e.g. early 
neuroprotection, delayed regeneration, etc.) and practical issues encountered in the clinical 
setting (e.g. need for patient stabilization prior to invasive interventions).
A recent study from the Steward lab reported that transplantation of a mixed population of 
rodent-derived glial and neuronal progenitors (which were not derived from iPS cells) into 
transection SCI resulted in ectopic engraftment of large numbers of cells at locations such as 
the central canal and pial surface of the spinal cord and the 4th ventricle [61], providing a 
note of caution when using transplantation of any class of NSC/NPC in SCI. This issue is 
particularly relevant to strategies employing cells derived from pluripotent sources such as 
ES and iPS cells given the possibility of incomplete and/or inefficient differentiation. For 
example, Tsuji and colleagues generated lines of both “safe” and “unsafe” neurospheres 
from mouse iPS cells [33]. In a mouse model of contusion SCI, the “safe” cells successfully 
survived, differentiated along mature CNS lineages and promoted functional recovery, 
serotonergic axon growth and remyelination without tumor formation. On the contrary, the 
“unsafe” neurospheres produced teratomas and associated functional impairment in the same 
SCI model. Unlike the Steward and Tsuji papers, the other iPS cell transplantation studies 
we describe in this review did not systematically assess distribution of transplant-derived 
cells throughout the neuraxis. In future experiments, it will be important for the field to 
assess cell fate at long-term time points post-transplantation, as well as possible ectopic 
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localization away from injections sites, to establish the safety of tested cells before 
proceeding to the clinic.
In all of these studies using iPS cells in SCI, transplanted cells differentiated into one or 
more mature CNS cell types (i.e. neurons, astrocytes and oligodendrocytes) in the injured 
spinal cord, although smaller percentages of undifferentiated nestin+ neural precursors were 
also seen even out to relatively late time points post-transplantation [33, 36, 53]. Along these 
lines, we noted the presence of a small residual population of proliferating graft-derived 
cells out to four weeks post-transplantation (the latest time point examined) when we 
injected hiPSAs into our SCI model. Even though we and others [36] did not observe overt 
tumor formation or extensive migration away from injection sites beyond only a few spinal 
segments, all of these studies collectively demonstrate the importance of efficient in vitro 
pre-differentiation prior to transplantation, which may require a combination of both 
positive selection of differentiated cell types and negative selection for residual pluripotent 
stem cells (and possibly even less immature NSCs and NPCs). Even with the use of this in 
vitro pre-selection, it will still be necessary to comprehensively conduct longer term follow-
up (preferably out to a year or more post-transplantation) of the safety of these cells in SCI 
animal models.
Mechanical allodynia (a form of neuropathic pain) was observed when iPS cell-derived 
astrocytes were transplanted into a contusion SCI model [54]. In addition to this work, other 
studies have similarly reported sensory hypersensitivity in SCI models accompanying 
transplantation of progenitor-derived astrocytes [62, 63], possibly due to increased neuronal 
plasticity induced by transplantation of immature astrocyte populations [64]. However, in a 
large body of work, we and others [60, 65, 66] have not found such increased sensitivity, 
including following hiPSA transplantation [60]. The discrepancy amongst these studies may 
be due to heterogeneity in the subtypes of astrocytes being injected [62, 67]. Nevertheless, 
this suggests caution with respect to potentially inducing unexpected functional outcomes 
after transplantation that can be very debilitating to patients, though this particular example 
is not specific to iPS cells.
A comprehensive summary of all these relevant papers using iPS cells in SCI animal models 
is presented in Table 1.
Transplantation of iPS cells in other spinal cord disease models
The application of iPS cells for treatment of spinal cord diseases is not exclusive to SCI. For 
example, Simone and colleagues transplanted iPS cell-derived NSCs into a rat model of 
Spinal muscular atrophy with respiratory distress type 1 (SMARD1). The authors reported a 
number of results similar to those already described in SCI models such as survival and 
differentiation of transplanted cells. They also found phenotypic improvement due to motor 
neuron protection, suggesting trophic influences of the transplanted cells. In support of this 
mechanism, through in vitro co-culturing studies with motor neurons generated from human 
SMARD1-iPS cells, they reported that iPS cell-derived NSCs increased motor neuron 
axonal length via neurotrophic factor production [68].
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Clinical implications of iPS cells for therapeutic transplantation in SCI
A number of practical issues will need to be addressed before moving iPS cell 
transplantation to the clinic in SCI and other nervous system diseases. Protocols for in vitro 
generation of iPS cells will need to be optimized (and possibly standardized), including the 
preferred somatic cell types used, the specific pluripotency factors and vectors used for 
reprogramming (discussed above), and the differentiation procedures used to efficiently 
generate cell types of interest from iPS cells without leaving residual undifferentiated cells. 
Importantly, these considerations will play a major role in preventing uncontrolled 
proliferation after transplantation.
Specifically with respect to targeting relative early events following SCI (e.g. secondary 
degeneration), autologous derivation of cells may not be relevant given the extended time 
needed (at least based on current induction technologies) to generate iPS cells and 
subsequently differentiate them prior to delivery. Instead, cells to be used for transplantation 
could be obtained from banks of immune/HLA-matched cells [69]. Given the need to 
extensively test iPS cell lines prior to transplantation into a patient, as well as the time that 
will be required for generating cells for each individual patient, this approach may actually 
be practically preferable to autologous derivation in some cases [70]. However, with such as 
allogeneic approach, the choice of appropriate immune suppression regimens will become a 
key factor, as will consideration of toxicity associated with long-term administration of such 
drugs. Nevertheless, autologous transplantation of iPS cells does seem practically plausible 
for transplanting cells into the chronic SCI condition (to target, for example, remyelination 
and axon regeneration) given the extended time frame from trauma to cell delivery.
As human stem cell lines have shown donor variability in SCI models [71], future studies 
will also need to investigate in vivo properties and therapeutic efficacy of human iPS cells 
derived from multiple donors in an attempt to move this approach towards clinical 
translation, particularly if banks of cells will be used to provide transplants for large 
numbers of patients. We may find, for example, that various donor lines differ in their 
therapeutic properties (e.g. levels and types of neurotrophins produced) and/or 
differentiation potential and consequently that certain lines are more suited to particular 
disease conditions depending on the mechanistic biological needs of a given disease or even 
disease sub-type.
With a number of studies having already demonstrated safety and therapeutic efficacy of iPS 
cell transplantation in animal models of SCI, clinical trials are beginning to move forward. 
For example, Okano and colleagues are currently preparing a clinical trial for SCI following 
sub-acute transplantation of iPS-derived NSCs/NPCs [72].
Conclusions
iPS cell technology provides a novel and clinically-relevant source of cells for CNS 
transplantation given that these cells avoid ethical issues associated with ES cell derivation 
and can be autologously derived from the patient in some cases, thereby avoiding toxic 
immune suppression. The iPS cell transplantation field is rapidly progressing, particularly 
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with respect both to testing therapeutic potential in SCI models and overcoming many of the 
practical hurdles associated with clinical translation. While a collective body of work has 
demonstrated that transplantation of CNS cells types derived from iPS cells into various 
models of SCI can promote histopathological and function recovery, many of these studies 
also provide important cautionary notes, mainly regarding the safety of the cell lines and the 
risk of tumor formation, which can be extremely detrimental to patients. Once practical 
issues associated with iPS cell transplantation are resolved and protocols for ensuring 
transplant safety are established, individualized therapies using iPS cells will be within 
closer reach for a wide range of CNS disease conditions, including SCI.
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